Application of a new preclinical drug screening system for cancer of the large bowel

Werner Scheithauer; Mary P. Moyer; Gary M. Clark; Daniel D. Von Hoff

doi:10.1007/BF00262734

Application of a new preclinical drug screening system for cancer of the large bowel

Werner Scheithauer, Mary P. Moyer, Gary M. Clark, Daniel D. Von Hoff

Producción científica: Article › revisión exhaustiva

12 Citas (Scopus)

Resumen

We report a prospective evaluation of three human, continuous colorectal cancer cell lines and a new semiautomated radiometric technique (Bactec system) as a primary screening procedure for cytotoxic compounds with activity against cancer of the large bowel. COLO 320DM, Ht-29, and the metastatic OM-1 colon cancer cell line that have previously been shown to yield clinically relevant information in terms of drug sensitivity patterns in humans were all tested against 11 new compounds currently being investigated in phase I or early phase II clinical trials. Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer.

Idioma original	English (US)
Páginas (desde-hasta)	31-34
Número de páginas	4
Publicación	Cancer chemotherapy and pharmacology
Volumen	21
N.º	1
DOI	https://doi.org/10.1007/BF00262734
Estado	Published - feb 1988

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Acceder al documento

10.1007/BF00262734

Otros archivos y enlaces

Citar esto

@article{03b13d0e1e0940f895694eb3453576cb,

title = "Application of a new preclinical drug screening system for cancer of the large bowel",

abstract = "We report a prospective evaluation of three human, continuous colorectal cancer cell lines and a new semiautomated radiometric technique (Bactec system) as a primary screening procedure for cytotoxic compounds with activity against cancer of the large bowel. COLO 320DM, Ht-29, and the metastatic OM-1 colon cancer cell line that have previously been shown to yield clinically relevant information in terms of drug sensitivity patterns in humans were all tested against 11 new compounds currently being investigated in phase I or early phase II clinical trials. Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer.",

author = "Werner Scheithauer and Moyer, {Mary P.} and Clark, {Gary M.} and {Von Hoff}, {Daniel D.}",

year = "1988",

month = feb,

doi = "10.1007/BF00262734",

language = "English (US)",

volume = "21",

pages = "31--34",

journal = "Cancer chemotherapy and pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Application of a new preclinical drug screening system for cancer of the large bowel

AU - Scheithauer, Werner

AU - Moyer, Mary P.

AU - Clark, Gary M.

AU - Von Hoff, Daniel D.

PY - 1988/2

Y1 - 1988/2

N2 - We report a prospective evaluation of three human, continuous colorectal cancer cell lines and a new semiautomated radiometric technique (Bactec system) as a primary screening procedure for cytotoxic compounds with activity against cancer of the large bowel. COLO 320DM, Ht-29, and the metastatic OM-1 colon cancer cell line that have previously been shown to yield clinically relevant information in terms of drug sensitivity patterns in humans were all tested against 11 new compounds currently being investigated in phase I or early phase II clinical trials. Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer.

AB - We report a prospective evaluation of three human, continuous colorectal cancer cell lines and a new semiautomated radiometric technique (Bactec system) as a primary screening procedure for cytotoxic compounds with activity against cancer of the large bowel. COLO 320DM, Ht-29, and the metastatic OM-1 colon cancer cell line that have previously been shown to yield clinically relevant information in terms of drug sensitivity patterns in humans were all tested against 11 new compounds currently being investigated in phase I or early phase II clinical trials. Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023851572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023851572&partnerID=8YFLogxK

U2 - 10.1007/BF00262734

DO - 10.1007/BF00262734

M3 - Article

C2 - 3342463

AN - SCOPUS:0023851572

SN - 0344-5704

VL - 21

SP - 31

EP - 34

JO - Cancer chemotherapy and pharmacology

JF - Cancer chemotherapy and pharmacology

IS - 1

ER -

Application of a new preclinical drug screening system for cancer of the large bowel

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto